Меню
Набор скоро начнётся NCT07752511

Anticipated Stigma, Illness Identity, and Quality of Life in Male Hypogonadism

— Наблюдательное Hypogonadism, Male Endocrine Disease Hypertension

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Hypogonadism, Male, Endocrine Disease, Hypertension. Базовые параметры: от 18 лет · Мужчины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Turkey (Türkiye)
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

The Impact of Anticipated Illness Stigma and Illness Identity on Quality of Life in Men With Hypogonadism: A Comparative Study With Other Chronic Endocrine Diseases

Обзор

This study aims to systematically compare the levels of anticipated illness stigma and illness identity among men diagnosed with hypogonadism to those of men with other chronic endocrine conditions (e.g., diabetes mellitus, hypothyroidism, and hypertension). Furthermore, it examines whether these psychosocial variables predict quality-of-life deterioration specifically within the hypogonadism cohort.

Подробное описание

Hypogonadism is a chronic endocrine condition characterized by subnormal serum testosterone levels. Unlike other chronic metabolic conditions, hypogonadism directly threatens core attributes of male gender identity, including sexual function, physical capacity, and reproductive potential. While biological manifestations and medical management are well documented, the psychosocial dimensions of hypogonadism, specifically anticipated stigma and illness identity, remain insufficiently explored in clinical research.

Anticipated stigma involves cognitive expectations of negative reactions, judgment, or discrimination from interpersonal, occupational, and healthcare environments. In conditions where illness poses a direct threat to gender role identity, anticipated stigma may be heightened compared to non-identity-threatening chronic conditions such as diabetes or hypertension. Furthermore, the degree to which an individual integrates the diagnosis into their self-concept (illness identity) may interact with anticipated stigma to exacerbate health-related quality-of-life impairments.

This study systematically evaluates anticipated stigma and illness identity in men with hypogonadism in comparison to age-matched controls with other chronic endocrine conditions treated in the same clinical setting. The primary objective is to determine whether anticipated stigma levels differ significantly between these groups and to examine the predictive capacity of anticipated stigma and illness identity on disease-specific symptom burden and quality-of-life outcomes within the hypogonadism cohort.

Первичные конечные точки

  • Chronic Illness Anticipated Stigma Scale (CIASS) Score [Срок оценки: Baseline (Single session, day 1)]
  • Brief Illness Perception Questionnaire (Brief IPQ) Score [Срок оценки: Baseline (Single session, day 1)]
Вторичные конечные точки (2)
  • Aging Males' Symptoms (AMS) Scale Score [Срок оценки: Baseline (Single session, day 1)]
  • Hospital Anxiety and Depression Scale (HADS) Score [Срок оценки: Baseline (Single session, day 1)]

Критерии участия

Критерии включения

Cases:

  • Male, aged 18 years or older.
  • Biochemically confirmed hypogonadism (total testosterone < 300 ng/dL with at least one clinical symptom).
  • Regular follow-up at the endocrinology outpatient clinic.
  • Fluent in reading and understanding Turkish.
  • Signed informed consent.

Controls:

  • Male, aged 18 years or older.
  • Diagnosed with diabetes, hypertension, or hypothyroidism under regular endocrinology follow-up.
  • Total testosterone ≥ 300 ng/dL.
  • Age-matched to a participant in the case group (±5 years).
  • Fluent in reading and understanding Turkish.
  • Signed informed consent.

Критерии исключения

  • Active psychiatric diagnosis (e.g., active psychosis, bipolar disorder).
  • Chronic inflammatory or rheumatological diseases affecting body composition (e.g., chronic kidney disease, IBD, rheumatoid arthritis, SLE, ankylosing spondylitis).
  • Uncontrolled co-existing endocrine conditions or severe complications (e.g., HbA1c > 8.0%, diabetic neuropathy/nephropathy/retinopathy, non-euthyroid state).
  • Cognitive impairment or dementia precluding questionnaire completion.
  • Klinefelter syndrome.
  • Literacy limitations preventing completion of self-report measures.
  • Additional control exclusion: Diagnosis or clinical suspicion of hypogonadism.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Случай-контроль

Центры проведения

Turkey (Türkiye) · 2 центра
  • Bingöl University Faculty of Physical Therapy and Rehabilitation — Bingoel
  • Malatya Training and Research Hospital — Malatya

Идентификаторы

NCT: NCT07752511 · AF-202604

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗